Full Text

Turn on search term navigation

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Skin wrinkles are an inevitable phenomenon that is brought about by aging due to the degradation of scleroprotein fibers and significant collagen reduction, which is the fundamental basis of anti-wrinkle technology in use today. Conventional treatments such as lasering and Botulinum toxin have some drawbacks including allergic skin reactions, cumbersome treatment procedures, and inefficient penetration of the anti-wrinkle products into the skin due to the high resistance of stratum corneum. Bearing this in mind, the cosmetic industry has exploited the patient-compliant technology of microneedles (MNs) to treat skin wrinkles, developing several products based on solid and dissolvable MNs incorporated with antiwrinkle formulations. However, drug administration via these MNs is limited by the high molecular weight of the drugs. Hollow MNs (HMNs) can deliver a wider array of active agents, but that is a relatively unexplored area in the context of antiwrinkle technology. To address this gap, we discuss the possibility of bioinspired 3D printed HMNs in treating skin wrinkles in this paper. We compare the previous and current anti-wrinkling treatment options, as well as the techniques and challenges involved with its manufacture and commercialization.

Details

Title
3D Printed Hollow Microneedles for Treating Skin Wrinkles Using Different Anti-Wrinkle Agents: A Possible Futuristic Approach
Author
Islam, Humayra 1 ; Taslima Sultana Poly 1 ; Zarin, Tasnim Tisha 1 ; Rahman, Samia 1 ; Ahmed Issa Jahangir Naveed 1 ; Ahmed, Alifa 1 ; Saraf, Nawar Ahmed 1 ; Hassan, Jasmin 1   VIAFID ORCID Logo  ; Md Jasim Uddin 2 ; Das, Diganta B 3   VIAFID ORCID Logo 

 Drug Delivery & Therapeutics Lab, Dhaka 1212, Bangladesh 
 Drug Delivery & Therapeutics Lab, Dhaka 1212, Bangladesh; Faculty of Engineering and Science, University of Greenwich, Chatham Maritime, Kent ME4 4TB, UK; School of Pharmacy, Brac University, 66 Mohakhali, Dhaka 1212, Bangladesh 
 Department of Chemical Engineering, Loughborough University, Epinal Way, Loughborough LE11 3TU, UK 
First page
41
Publication year
2023
Publication date
2023
Publisher
MDPI AG
e-ISSN
20799284
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2806517508
Copyright
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.